SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Aryzta AG (ARZTY) trades at a trailing P/E of 18.3. Trailing earnings yield is 5.47%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (75/100, Pass) — P/E is below market average (18.3); PEG ≤ 1.0 — Peter Lynch undervalued (0.03); earnings yield beats bond yields (5.47%).
- PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 5.47% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 71/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ARZTY
Valuation Multiples
P/E (TTM)18.3
Forward P/EN/A
PEG Ratio0.03
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.87
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.41
Book Value / Share$0.00
Revenue / Share$8.60
FCF / Share$0.00
Yields & Fair Value
Earnings Yield5.47%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.45 |
$3.88B |
$67.01M |
1.7% |
| 2017 |
$-5.23 |
$3.8B |
$-907.77M |
-23.9% |
| 2018 |
$-2.81 |
$3.44B |
$-469.98M |
-13.7% |
| 2019 |
$-0.04 |
$3.38B |
$-29.2M |
-0.9% |
| 2020 |
$-0.24 |
$1.67B |
$-1.09B |
-65.4% |
| 2021 |
$-0.14 |
$1.53B |
$-235.8M |
-15.5% |
| 2022 |
$-0.02 |
$1.76B |
$900K |
0.1% |
| 2023 |
$0.03 |
$2.12B |
$112M |
5.3% |
| 2024 |
$0.05 |
$2.19B |
$129.6M |
5.9% |
| 2025 |
$0.41 |
$2.14B |
$107.87M |
5.1% |
